Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 103,832
  • Shares Outstanding, K 126,624
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,610 K
  • 60-Month Beta 1.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.81
Trade ATOS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.19
  • Most Recent Earnings -0.06 on 11/07/22
  • Next Earnings Date 11/21/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 100.91% ( -30.59%)
  • Historical Volatility 53.81%
  • IV Percentile 48%
  • IV Rank 30.38%
  • IV High 322.49% on 01/13/22
  • IV Low 4.24% on 08/10/22
  • Put/Call Vol Ratio 0.03
  • Today's Volume 41
  • Volume Avg (30-Day) 316
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 110
  • Open Int (30-Day) 61,216

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7600 +7.89%
on 11/22/22
1.0600 -22.64%
on 10/27/22
-0.0930 (-10.19%)
since 10/25/22
3-Month
0.7600 +7.89%
on 11/22/22
1.0600 -22.64%
on 10/27/22
-0.1401 (-14.59%)
since 08/25/22
52-Week
0.7600 +7.89%
on 11/22/22
2.3300 -64.81%
on 11/29/21
-1.4700 (-64.19%)
since 11/24/21

Most Recent Stories

More News
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop...

ATOS : 0.8200 (+4.14%)
Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

Atossa Plans to Initiate a New Development Path in Patients with Compromised Lung-Function Resulting from Cancer Treatment...

ATOS : 0.8200 (+4.14%)
Atossa: Acquiring CAR-T Company Would Be a Great Move, Says Analyst

According to a recent 8-K filed by Atossa Therapeutics (ATOS), the biotech has signed a letter agreement with a private, venture-backed American company. One which is creating CAR-T medicines which have...

ATOS : 0.8200 (+4.14%)
Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations

SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop...

ATOS : 0.8200 (+4.14%)
Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference

SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop...

ATOS : 0.8200 (+4.14%)
Atossa Therapeutics to Present at the Q2 Investor Summit Conference

SEATTLE, April 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop...

ATOS : 0.8200 (+4.14%)
Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION...

ATOS : 0.8200 (+4.14%)
Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference

SEATTLE, March 23, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop...

ATOS : 0.8200 (+4.14%)
Noteworthy Friday Option Activity: ATOS, SFT, CXW

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Atossa Therapeutics Inc , where a total of 13,627 contracts have traded so far, representing...

ATOS : 0.8200 (+4.14%)
Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen

SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop...

ATOS : 0.8200 (+4.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

3rd Resistance Point 0.9027
2nd Resistance Point 0.8625
1st Resistance Point 0.8413
Last Price 0.8200
1st Support Level 0.7799
2nd Support Level 0.7397
3rd Support Level 0.7185

See More

52-Week High 2.3300
Fibonacci 61.8% 1.7303
Fibonacci 50% 1.5450
Fibonacci 38.2% 1.3597
Last Price 0.8200
52-Week Low 0.7600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar